期刊
FEMS MICROBIOLOGY REVIEWS
卷 44, 期 6, 页码 684-700出版社
OXFORD UNIV PRESS
DOI: 10.1093/femsre/fuaa017
关键词
clinical trials; phage resistance; phage engineering; phage cocktails; regulatory framework; One-Health
类别
资金
- Portuguese Foundation for Science and Technology (FCT) [PTDC/BBB-BSS/6471/2014 (POCI-01-0145-FEDER-016643)]
- European Regional Development Fund under the scope of Norte2020Programa Operacional Regional do Norte [NORTE-01-0145-FEDER-000004, UIDB/04469/2020]
- FCT [SFRH/BPD/116187/2016, SFRH/BD/117365/2016]
- Fundação para a Ciência e a Tecnologia [SFRH/BD/117365/2016, SFRH/BPD/116187/2016] Funding Source: FCT
Antibiotic resistance is a major public health challenge worldwide, whose implications for global health might be devastating if novel antibacterial strategies are not quickly developed. As natural predators of bacteria, (bacterio)phages may play an essential role in escaping such a dreadful future. The rising problem of antibiotic resistance has revived the interest in phage therapy and important developments have been achieved over the last years. But where do we stand today and what can we expect from phage therapy in the future? This is the question we set to answer in this review. Here, we scour the outcomes of human phage therapy clinical trials and case reports, and address the major barriers that stand in the way of using phages in clinical settings. We particularly address the potential of phage resistance to hinder phage therapy and discuss future avenues to explore the full capacity of phage therapy.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据